Skip to main content

Table 1 Baseline characteristics of patients with second haemoglobin measurement in first six months of ART initiation

From: Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings

Characteristic

All patients (n = 3105)

Patients with early severe anaemia (n = 109)

Gender

  

   Female

2065 (67%)

80 (73%)

   Male

1040 (23%)

29 (26%)

Age (yrs) median (IQR)

36 (31,42)

37 (30,41)

BMI (kg/m2) median

  

(IQR)

20 (18,23)

18 (17,22)

WHO stage

  

I-II

937 (30%)

25 (23%)

III- IV

2168 (70%)

84 (76%)

CD4 T cell count,

  

Median (IQR)

101 (33, 173)

65 (21,144)

200+

426 (14%)

12 (11%)

50-199

1589 (51%)

47 (43%)

<50

942 (30%)

44 (40%)

Missing

148 (5%)

6 (6%)

HB g/dL

  

≥8

2959 (95%)

79 (72%)

<8

146 (5%)

30 (28%)

MCV, median (IQR)

84 (79,90)

79 (74,86)

≥80fL

2225 (72%)

54 (50%)

<80fL

880 (28%)

55 (50%)

TB

  

No

3035 (98%)

93 (85%)

Yes

70 (2%)

16 (15%)

ART Regimen

  

d4T-containing

1965 (63%)

65 (60%)

AZT-containing

1140 (37%)

44 (40%)

  1. BMI = body mass index, HB = haemoglobin, MCV = mean corpuscular volume, IQR = interquartile range, TB = tuberculosis, ART = antiretroviral therapy, d4T = stavudine, AZT = zidovudine, OR = odds ratio